- Home
- NKTR
NKTR
Nektar Therapeutics
as 03-25-2025 10:39am EST
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 160.4M | IPO Year: | 1994 |
| Target Price: | $5.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $1.93 | Next Earning Date: | 03-12-2025 |
| Revenue: | $98,427,000 | Revenue Growth: | 9.21% |
| Revenue Growth (this year): | -11.67% | Revenue Growth (next year): | -0.72% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Feb 19 '25 | Sell | $1.01 | 11,040 | $11,150.40 | 324,292 | |
| ROBIN HOWARD W | NKTR | President & CEO | Feb 19 '25 | Sell | $1.01 | 23,774 | $24,011.74 | 1,086,901 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Feb 19 '25 | Sell | $1.01 | 10,300 | $10,403.00 | 316,604 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil
PR Newswire
6 days ago
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
MT Newswires
12 days ago
Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer
Zacks
12 days ago
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
MT Newswires
12 days ago
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6
Simply Wall St.
12 days ago
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
13 days ago
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
Thomson Reuters StreetEvents
13 days ago
Q4 2024 Nektar Therapeutics Earnings Call
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.